ENABLE-2 expanding its project portfolio with two new programmes


Antibiotic platform ENABLE-2 welcomes two new programmes: the "Ornicidine" programme, a scientific collaboration between Leiden University in the Netherlands and Queen's University Belfast in Northern Ireland; and the "BamA Inhibitors" programme, based at the German Justus Liebig University Giessen and Fraunhofer IME.

Anders Karlén, coordinator at ENABLE-2 and Professor at Uppsala University
Anders Karlén, coordinator at ENABLE-2 and Professor at Uppsala University

Only three months after ENABLE-2 included the Scottish programme Strathclyde Minor Groove Binders in its project portfolio, the antibiotic platform welcomes two new programmes. In early September, a collaboration agreement was signed with the "Ornicidine" programme – focusing on a novel class of antibacterial agents active against multi drug-resistant Gram-negative bacteria – led by Nathaniel Martin, Professor at Leiden University, and Dr. Stephen Cochrane, researcher at Queen's University Belfast.

“We are very happy with the great interest ENABLE-2 is generating in Europe. The fact that we are now expanding with two new and highly promising programmes based in the Netherlands, Northern Ireland and Germany raises our international presence to another level,” states Anders Karlén, Coordinator at ENABLE-2 and Professor of Computer-aided drug design.

Dr. Till F. Schäberle, Justus Liebig University Giessen
Dr. Till F. Schäberle, Justus Liebig University Giessen

Monday 18 September, ENABLE-2 announced that they are also starting a collaboration with the "BamA Inhibitors" programme under the scientific direction of Dr. Till F. Schäberle, researcher at Justus Liebig University Giessen and Fraunhofer IME, focusing on Novel antibiotics that hit a new target against Gram-negative bacteria.

In June, ENABLE-2 held its first Annual Meeting with 40 participants from seven countries visiting Uppsala to discuss antibiotic discovery and the future development of our current portfolio of programmes. 

"At the Anunal meeting, a decision was made to go from a model of individually announced Open Calls to a model of continuously accepting new applications to join ENABLE-2. By reaching out to academic groups throughout Europe we hope to ensure that we continue to attract the highest quality of applications for evaluation by our expert Portfolio Management Committee", says Anders Karlén.


  • ENABLE-2 is a platform that offers project support in the development of antibacterial drugs.
  • ENABLE-2 is coordinated at the Faculty of Pharmacy, Uppsala University.



Anders Karlén, ProfessorAnders Karlén, Professor
Coordinator, ENABLE-2

Diarmaid Hughes, Deputy coordinatorDiarmaid Hughes, Professor
Co-coordinator, ENABLE-2

Text: Magnus Alsne, photo: Mikael Wallerstedt a o

Research news

Last modified: 2021-05-31